Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease

Detalhes bibliográficos
Autor(a) principal: Gião, T
Data de Publicação: 2020
Outros Autores: Saavedra, J, Cotrina, E, Quintana, J, Llop, J, Arsequell, G, Cardoso, I
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://hdl.handle.net/10216/142502
Resumo: Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions. In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer’s disease (AD). We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aß peptides, and the proposed mechanisms underlying TTR neuroprotection in AD. We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics.
id RCAP_29e498339aa5c0e84803c40478c6cf3c
oai_identifier_str oai:repositorio-aberto.up.pt:10216/142502
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s diseaseTransthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions. In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer’s disease (AD). We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aß peptides, and the proposed mechanisms underlying TTR neuroprotection in AD. We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics.MDPI20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://hdl.handle.net/10216/142502eng1661-659610.3390/ijms21062075Gião, TSaavedra, JCotrina, EQuintana, JLlop, JArsequell, GCardoso, Iinfo:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-29T14:46:39Zoai:repositorio-aberto.up.pt:10216/142502Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T00:08:13.886790Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
title Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
spellingShingle Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
Gião, T
title_short Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
title_full Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
title_fullStr Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
title_full_unstemmed Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
title_sort Undiscovered roles for transthyretin: From a transporter protein to a new therapeutic target for Alzheimer’s disease
author Gião, T
author_facet Gião, T
Saavedra, J
Cotrina, E
Quintana, J
Llop, J
Arsequell, G
Cardoso, I
author_role author
author2 Saavedra, J
Cotrina, E
Quintana, J
Llop, J
Arsequell, G
Cardoso, I
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Gião, T
Saavedra, J
Cotrina, E
Quintana, J
Llop, J
Arsequell, G
Cardoso, I
description Transthyretin (TTR), an homotetrameric protein mainly synthesized by the liver and the choroid plexus, and secreted into the blood and the cerebrospinal fluid, respectively, has been specially acknowledged for its functions as a transporter protein of thyroxine and retinol (the latter through binding to the retinol-binding protein), in these fluids. Still, this protein has managed to stay in the spotlight as it has been assigned new and varied functions. In this review, we cover knowledge on novel TTR functions and the cellular pathways involved, spanning from neuroprotection to vascular events, while emphasizing its involvement in Alzheimer’s disease (AD). We describe details of TTR as an amyloid binding protein and discuss its interaction with the amyloid Aß peptides, and the proposed mechanisms underlying TTR neuroprotection in AD. We also present the importance of translating advances in the knowledge of the TTR neuroprotective role into drug discovery strategies focused on TTR as a new target in AD therapeutics.
publishDate 2020
dc.date.none.fl_str_mv 2020
2020-01-01T00:00:00Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://hdl.handle.net/10216/142502
url https://hdl.handle.net/10216/142502
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 1661-6596
10.3390/ijms21062075
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv MDPI
publisher.none.fl_str_mv MDPI
dc.source.none.fl_str_mv reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799136007947288576